

**SCI REUNION DU PRINTEMPS 1992
PREMIERE ANNONCE**

**1992 SPRING CSI MEETING
FIRST ANNOUNCEMENT**



BULLETIN

CANADIAN SOCIETY FOR IMMUNOLOGY

SOCIETE CANADIENNE D'IMMUNOLOGIE

**SEPTEMBER 1991
V. 21, No. 2**

0068-9653

Preliminary Announcement



**Canadian Society for Immunology -- Spring '92 Meeting
Societe Canadienne d'Immunologie Reunion du Printemps
1992**

**March 13-16, 1992/ le 13-16 mars, 1992
Auberge Mont Gabriel - Mont Rolland, Quebec**

The meeting will consist of a symposium each morning, afternoon workshops and a poster session each evening after dinner.

Les matinées sont réservées pour les conférences et les soirées pour les séances d'affichage. Les après-midi sont libres pour les ateliers.

Program/Programme

Symposium I Immunoglobulin genes

Chairperson: Gill Wu (Toronto)
co-chair: Michael Ratcliffe (Montreal)

Symposium II MHC-protein Interactions

Chairperson: Tania Watts (Toronto)
co-chair: Rafik Sekaly (Montreal)

Symposium III Brain Immune Interactions

Chairperson: Jack Antel (Montreal)
co-chair: Larry Guilbert (Edmonton)

Workshops:	I	Immunoparasitology	Chair: Chris Chaddee (Montreal)
	II	Tolerance and Anergy	Chair: Hung-Sia Teh (Vancouver)
	III	Accessory Molecules	Chair: Rafik Sekaly (Montreal)
	IV	T cell Development and cell surface markers	Chair: Linda Pilarski (Edmonton)

Canadian Society for Immunology - Spring '92 Meeting

The 1992 Spring CSI meeting will be held in Mont Gabriel, Quebec from the evening of Friday 13th March to the morning of Monday 16th March. The Cinader Lecture will be on Friday evening, the Symposia will be on Saturday, Sunday and Monday mornings and the workshops will be on Saturday and Sunday late afternoons. Saturday and Sunday evenings will be for poster sessions. The hotel registration package includes free ski passes. Registration and abstract packages will be mailed in October, if you have received this CSI bulletin you will get the package, otherwise write or FAX to Michael Ratcliffe, McGill University. As in previous years there will be student travel bursaries for this meeting and prizes awarded for the best student posters, details of awards will be provided in the registration package.

Société Canadienne d'Immunologie Réunion du Printemps 1992

L'assemblée SCI du printemps 1992 aura lieu au Mont Gabriel, Québec. La réunion débutera dans la soirée du vendredi 13 mars et se conclura dans la matinée du lundi 16 mars. La présentation Cinader se donnera le vendredi soir, les conférences se tiendront les samedi, dimanche et lundi matins et les ateliers auront lieu les samedi et dimanche après-midi. Les soirées de samedi et dimanche seront réservées pour les séances d'affichage. Des billets de ski sont inclus dans les frais d'inscription à l'hôtel. Les inscriptions pour la réunion, le résumé et l'hôtel vous seront postés en octobre. Si vous avez reçu ce bulletin du SCI vous recevrez sans faute ces informations. Dans le cas échéant veuillez écrire ou télécopier votre demande à Michael Ratcliffe de l'Université McGill. Comme dans les années précédentes des bourses pour les frais de voyage et des prix pour les meilleures affiches seront attribués aux étudiants. Les détails des prix seront fournis dans le nécessaire d'inscription.

Early registration deadline: **6th January 1992**

La date limite pour la pré-inscription:

Abstract deadline: **6th January 1992**

La date limite de réception du résumé:

Hotel registration deadline: **1st February 1992**


La date limite pour les réservations à l'hôtel:

Student travel bursary deadline: **6th January 1992**

Bourse de voyage pour les étudiants:

Michael J.H. Ratcliffe,
Department of Microbiology and Immunology,
McGill University,
3775 University St.,
Montreal, Quebec,
H3A 2B4

FAX (514)-398 7052



Mont-Rolland [Québec] Canada J0R 1G0
[514] 229-3547 Montréal : [514] 861-2852 [Fax] 229-7034

which has been selected by your Convention Committee,
has the great pleasure of welcoming the members of
the CANADIAN SOCIETY OF IMMUNOLOGY
for their "SPRING MEETING"
to be held in March 1992

CONFERENCE DATES:

Arrival:	FRIDAY, MARCH 13 th 1992
Departure:	MONDAY, MARCH 16 th 1992

RATES: \$ 78.00 + GST, per day, per person, TRIPLE occupancy
\$ 88.00 + GST, per day, per person, DOUBLE occupancy
\$125.00 + GST, per day, SINGLE occupancy

including: overnight accommodation
buffet breakfast
buffet lunch
set dinner menu
all indoor sport activities
ski lift
all gratuities

N.B.: SAME RATES WILL APPLY FOR PRE OR POST CONFERENCE RESERVATIONS.

* * *

For reservation, please return the enclosed registration form, duly completed, with your deposit of \$75.00, in order to guarantee your accommodation.

WISHING YOU A SAFE TRIP AND LOOKING FORWARD TO HAVING YOU AS OUR GUESTS

* * * * *



Station touristique

Mont-Rolland [Québec] Canada J0R 1G0
[514] 229-3547 Montréal : [514] 861-2852 [Fax] 229-7034

LA STATION TOURISTIQUE MONT GABRIEL

qui a été choisie comme site pour votre Congrès
a le plaisir de souhaiter la bienvenue aux membres de la

SOCIÉTÉ CANADIENNE D'IMMUNOLOGIE

lors de leur "REUNION PRINTANIERE" de mars 1992

DATE DU CONGRES: Arrivée: VENDREDI 13 MARS 1992

Départ: LUNDI 16 MARS 1992

TARIFS:

\$ 78.00 + TPS, par jour, par personne, occupation TRIPLE
\$ 88.00 + TPS, par jour, par personne, occupation DOUBLE
\$125.00 + TPS, par jour, occupation SIMPLE

incluant: logement
petit déjeuner "style buffet"
dîner "style buffet"
souper - menu fixe
toutes les activités sportives intérieures
billet de ski
tous les frais de service

N.B.: LES MEMES TARIFS SERONT APPLICABLES POUR TOUTES RESERVATIONS
AVANT OU APRES LE CONGRES.

Pour réserver, veuillez retourner le formulaire ci-joint, dûment complété,
accompagné d'un dépôt de \$75.00, afin de garantir votre réservation.

BON VOYAGE ET AU PLAISIR DE VOUS COMPTER PARMI NOS INVITES

Immunology at the University of Alberta

Belosevic, Mike (B.Sc., M.Sc., Manitoba; Ph.D., McGill) Dept. of Zoology. Immunobiology of host-parasite interactions: molecular mechanisms of host defense against protozoan parasites *Leishmania* and *Giardia*; lymphokine regulation of macrophage antimicrobial activities; biology of cytokines in teleosts.

Bleackley, R. Chris (B.Sc., Ph.D., Birmingham) Dept. of Biochemistry. Molecular analysis of the effector mechanism operative in cytotoxic T lymphocytes and the control of gene expression during T cell activation.

Elliott, John (M.D., Ph.D., Alberta) Dept. of Medical Microbiology. The use of eucaryotic expression and antibody 'panning' to clone and study new surface antigens from the parasite *Plasmodium falciparum*, and 2) the use of genetic engineering and PCR to define T-cell receptor repertoire and to clone potential T-cell auto-antigens in autoimmune disease.

Halloran, Philip F. (M.D., Toronto; F.R.C.P.; Ph.D., London, U.K.) Dept. of Medicine. Interferon regulation of MHC expression in the host response to infections, autoimmunity and transplantation - significance and mechanisms.

Kane, Kevin (A.B., Ph.D., California) Dept. of Immunology. We study events involved in class I MHC-restricted antigen processing and presentation to cytotoxic T lymphocytes (CTL), focussing on the molecular interactions of CTL with antigen bearing cells that result in CTL recognition and transmembrane signalling.

Kunimoto, Dennis (M.D., Alberta; F.R.C.P. (C), Manitoba) Dept. of Medical Microbiology. Molecular and cellular characterization of B cell differentiation and the role of IL-5 and its receptor in immune response.

Longenecker, B. Michael (B.A., Ph.D., Missouri) Dept. of Immunology. The main focus of my program is Active Specific Immunotherapy (ASI) of cancer using novel cancer "vaccines" which are designed to be highly immunogenic chemically defined formulations generated using novel synthetic carbohydrate, peptide and glycopeptide cancer associated epitopes. Valid animal models are being used to test and select the most effective "vaccine" formulations and three of the most effective "vaccines" have now been tried in phase I clinical trials in ovarian, breast, colon and melanoma patients with very promising results. Many of the target epitopes being studied are present on novel cancer-associated cell surface mucin molecules which are being biochemically characterized and cloned in our laboratory.

Mosmann, Timothy R. (B.Sc., Natal, S.A.; B.Sc. Hons., Rhodes, S.A.; Ph.D., British Columbia) Dept. of Immunology. Dr. Mosmann's research focuses on the functions and cross-regulation of different T cells secreting different patterns of cytokines.

Ostergaard, Hanne (B.S., Ph.D., California) Dept. of Immunology. CD45 is a protein tyrosine phosphatase (PTPase) that is expressed on all cells of hematopoietic origin. The role of CD45 in lymphocyte activation and the regulation of CD45 PTPase activity during this process is currently being examined.

Pabst, Henry F. (M.D., Alberta) Dept. of Pediatrics. Ontogeny of human immune response. Vaccine studies in children.

Paetkau, Verner H. (B.Sc., Alberta; M.Sc., Ph.D., Wisconsin) Dept. of Biochemistry. The research in Dr. Paetkau's laboratory is directed at producing a detailed molecular understanding of how T lymphocytes are regulated, in particular, how the cytokine genes are controlled by intracellular mechanisms. The metabolism of cytokine mRNA is being studied in terms of both induction of transcription and mRNA degradation. Another subject of interest is the relationship of the Mouse Mammary Tumor Virus to lymphocyte tumor generation.

Pilarski, Linda M. (B.Sc., Illinois; Ph.D., Adelaide) Dept. of Immunology. Dr. Pilarski's research centers on an analysis of human B and T lymphocyte differentiation with an emphasis on the functional roles of cell surface molecules in mediating interaction between cells and between a developing lymphocyte and its microenvironment. Of particular interest are CD45, the leukocyte common antigen, which includes a family of isoforms differentially expressed during T and B cell differentiation, and the adhesion molecules (integrins, selectins) which mediate interactions between the lymphocyte and the extracellular matrix and/or endothelial stromal cells.

Poppema, Sibrand (M.D., Ph.D., Groningen; Pathologist, Netherlands; F.R.C.P.(C), Pathology, Canada) Dept. of Pathology. In general, Dr. Poppema's research is in the pathogenesis of lymphomas: Pathogenesis of Hodgkin's disease; Lymphomagenesis of follicular lymphomas; Diversity of leukocyte common antigen (CD45).

Rabinovitch, Alex (M.D., McGill) Dept. of Medicine. Immunopathogenesis prevention, and treatment of autoimmune, insulin-dependent diabetes mellitus (IDDM). Our laboratory has demonstrated that certain cytokines (IL-1, TNF- α/β , IFN- γ) can interact synergistically and lyse pancreatic islet β -cells in vitro. Since these insulin-producing islets β -cells are destroyed by infiltrating mononuclear cells (macrophages and T-cells) in autoimmune IDDM, our findings suggest that cytokine products of macrophages (IL-1, TNF- α) and T-cells (IFN- γ , TNF- β) may mediate the cytotoxic effects of the infiltrating mononuclear cells on islet β -cells, resulting in IDDM. Our current studies focus on cytokine gene expression and protein production by immunologic cells which infiltrate the islets in animal models with IDDM, the BB rat and NOD mouse. Other studies are directed at identifying the molecular mechanisms of cytokine-induced islet β -cell injury, in particular the role of oxygen free radicals.

Shaw, Andrew R.E. (B.Sc. Hons., London; Ph.D., Southampton) Dept. of Medicine. The molecular basis of cell adhesion as it relates to the functioning of the immune system, the leukemic process, the malignant and metastatic phenotype, and disorders of the cardiovascular system related to platelet deposition. Of primary interest is the definition of the function of CD9, a signal-initiating molecule involved in the generation of signals enhancing cellular adhesiveness, and a member of a newly recognized family of multiply inserted "4-path" transmembrane proteins of uncertain function. Our goal is to identify adhesion, and signalling molecules physically and functionally linked to CD9 and to the signalling pathway it subserves, and to define their functional interaction.

Singh, Bhagirath (B.Sc., M.Sc., Rajastrar; Ph.D., CDRI, Agra) Dept. of Immunology. Major areas of research are: Processing and recognition of antigens by T cells, structure and function relationship of MHC molecules, T cell mediated autoimmune diabetes, self antigens and modulation of diabetes by immunotherapy.

Wegmann, Thomas G. (B.A., Ph.D., Wisconsin) Dept. of Immunology. Dr. Wegmann is currently involved in three areas of research: 1) The role of cytokines in trophoblast differentiation and HIV infectability; 2) The feasibility of using antibody facilitation for bone marrow transplantation as a no-fault procedure for gene therapy; and 3) Novel methods of ELISA diagnostics.

Yacyshyn, Bruce [B.Sc., M.D., Alberta; F.R.C.P.(C)] Dept. of Medicine. Dr. Yacyshyn's main research interest is the immunological interactions of the mucosal immune system. Specific interests include immunological alterations identifiable with inflammatory bowel disease, i.e., cellular immune differences in cellular immune activation and lymphokine activity.



CFBS SCIENCE POLICY ACHIEVEMENTS AND IMPACTS

1985-1991

Prepared by: Clément Gauthier, Ph.D.
Science Policy Officer

RESEARCH FUNDING

-February 1985 -- Supplementary budgets are requested for the granting councils (GC) ** \$31m (MRC) and \$21m (NSERC) are allocated on April 1985.

-April 1985 -- The incorporation of these supplementary budgets to the base budgets of the councils is requested ** Implemented in February 1986 by the Government.

-October 1985 -- A long-term funding plan and an increased funding are requested for the GCs ** In Feb. 1986, Government announces a 4% increase in the budget of the GCs for 1986-87, commits money for five years equivalent to the base budget and introduces the matching policy allowing for a yearly 6% growth in their budget from 1986-87 to 1990-91.

-April 1986 -- Major modifications to the draft regulations on the matching policy are requested to ensure easy access to maximal matching contributions for the GCs ** Finance Department implements 80% of our recommendations in Sept. 1986.

-December 1986 -- A \$300m in catch-up federal funds for university research is requested followed by a request to implement the doubling in the base budget of the GCs as recommended in Dec. 1987 by the National Advisory Board on S & T (NABST) to Prime Minister Mulroney ** The base budget of the GCs is increased by \$200m over five years (NSERC: \$103m; MRC: \$61m) starting in 1988-89.

-April 1987 -- Supplementary budgets are requested for the GCs. ** A one time supplement to the matching policy (MRC: \$3m; NSERC: \$6m) is announced on August 1987.

-January 1988 -- The implementation of the NABST's recommendation is requested and CFBS is a keyplayer in rechannelling \$200m from the \$1.5 billion (Innovaction) announced in Jan. 1988 towards the GCs: announced in May 1988.

-May 1988 -- CFBS issues recommendation regarding the application rules for the Networks of Centres of Excellence (\$240m announced in Jan. 1988) before the House of Commons Committee on Research, Science and Technology. ** Six of our seven recommendations have been implemented and the Committee's report recommended the implementation of the NABST's recommendation to double the budgets of the GCs to ensure Canada has enough people to staff future centres of excellence.

-April 1989 -- Request and suggestions for coherent educational and scientific policies that will ensure that by year 2000 Gross Expenditures on Research and Development (GERD) in Canada will amount to 2.5% of the Gross Domestic Product (GDP), including the research carried out by universities, the federal government and other performing sectors. ** Though the federal government hasn't yet adopted a national GERD target, both the Council of Science and Technology Ministers (Sept. 13, 1989), and the National Forum of Science and Technology Advisory Councils (Aug. 12, 1989; May 27, 1990), the provincial counterparts to the NABST, are investigating ways to achieve the proposed target within the deadline introduced by the CFBS; the proposed target has also been endorsed on Dec. 1990 by the all-party House of Commons on Industry, Science and Technology, with year 2005 as deadline.

-December 1989 -- In agreement with the GCs, CFBS endorses the conclusions of the Final Report on the Evaluation of the Matching Policy and requests that the matching contributions be rolled into the base budgets of the GCs and that these budgets be doubled as recommended by the NABST. ** The Feb. 1990 federal budget announcements specifically excluded the GCs from the 5% restraint in annual growth for two years applying to other S&T programs, allowing a 9.0% and 9.7% budgetary increase for NSERC and MRC respectively to take place in 1990-91.

-March to October 1990 -- The maintenance of the former matching contributions (21% of the total GC's budget), their rolling into their base budget and the implementation of the NABST' recommendation are requested. ** The Feb. 26 1991 federal budget confirms the maintenance of the former matching contributions into the budget of the GCs for 1991-92, and exempts the GCs for 1991-92 from the 3% cap imposed to all other S & T activities and most government expenditures, allowing a 3.7% increase in their base budget for 1991-92.

-October 1990 -- CFBS successfully mounts a letter-writing campaign which prevents the diversion of NSERC's funds (\$90 m/year) towards the support of scientific megaprojects such as the TRIUMF-KAON factory.

DOUBLING INDUSTRY'S INVESTMENT IN CANADIAN R&D THROUGH BILL C-22, AN ACT TO AMEND THE PATENT ACT FOR PHARMACEUTICAL INDUSTRY

From 1984 until Bill C-22 received the royal sanction on Nov. 19, 1987, CFBS has been a keyplayer at every stage of the bill.

Before the introduction of the Bill: CFBS submitted a Brief to the Commission of Inquiry of the Pharmaceutical Industry (Eastman Commission) on August 1984, and issued a Position Paper on the report of the Commission on October 1985, after an extensive consultation with Heads of Departments of Pharmacology of 17 major Canadian universities and the 31 members of the Science Policy Committee of the CFBS. CFBS representatives met with the Minister of Consumers and Corporate Affairs to present the Position Paper on Oct. 29, 1985, and the first Draft Legislation was made public on July 27, 1986 by Minister Côté who was then replaced by Minister Harvie Andre.

Improving the Bill: CFBS submitted the following series of amendments to Bill C-22 on August 27, 1986 designed to link patent protection to the amount spent by pharmaceutical companies on R & D done in Canada: (i) that government's own projections for rate of growth in R & D investments be incorporated as essential mandatory increases, not as estimated increases ** (implemented); (ii) that the Patented Medicine Prices Review Board monitor the performance of the industry in R & D investments and make it, in addition to drug prices, the two criteria allowing for reduction or elimination of the exclusivity period ** (implemented); (iii) that a definition of research that focus on the development of new knowledge directly relevant to new drugs be incorporated to the amendments ** (not implemented).

On January 12, 1987, CFBS appeared before the Legislative Committee of the House of Commons on Bill C-22 and called for an additional amendment that would compel pharmaceutical companies to

CFBS' relationships with the granting councils improved tremendously since the establishment of liaison committees with both MRC and NSERC in 1985. In addition to on-going contact through the Science Policy Office, policy issues and funding allocations are discussed formally at twice a year by members of the committees. **CFBS is invited to nominate representatives of the various committees of both agencies, and our comments and recommendations always receive due consideration.

CFBS revitalized and led The National Consortium of Scientific and Educational Societies from 1985 to 1990. The Consortium is an informal coalition representing 55,000 researchers and educators from various disciplines across Canada. The Consortium holds monthly meetings to discuss and take action relating to policies on research and postsecondary education, and organizes a yearly lobby of parliamentarians and government administrators.

* * * * *

"The Consortium is the most effective lobby I have experienced in my 4 years... I am impressed by the persistence of the lobby and its range... No one else does lobbying regularly and so well".

-Mr. H. Rogers, Deputy Minister, Industry, Science and Technology Canada, March 10, 1991

"Your leadership role in the activities of the Consortium have been a key element in the success of an informative lobbying week... I hope the Consortium will remain the driving force with regards to the process of establishing priorities and coordinating activities. Were scientific bodies to engage in separate lobbying efforts, the end result would be much less efficient".

-The Hon. L. Bouchard, Minister of Environment, March 7, 1990

"The contribution of the Consortium to build a national consensus on the vital issues related to university research and training has been significant. I respect and rely upon your members as a valuable source for advice and expertise in the formulation of programs and policies".

-The Hon. W. Winegard, Minister for Science, Feb. 13, 1989

"I would like to commend the CFBS for having assumed successfully the leadership of the Consortium. You successfully faced this challenge and played a most important role in bringing Canadian scientists together".

-Dr. P. Bois, President, MRC, Dec. 18, 1989

NOTE: These highlights are gleaned from a 26-page summary of activities. Further information can be obtained from the Science Policy Office of the CFBS upon request.

April 1991

JPW Gilman, DVM
Executive Director
Tel: (613) 232-3260

Fondation de recherche

JOSEPH F. MORGAN
Research Foundation

205-151 Slater St.
Ottawa, Ontario K1P 5N1
Tel: (613) 563-1236
Ext. 339
Fax: (613) 563-9745

1991.05.08

Dr. Kent Hayglass
Editor, CSI
Department of Immunology
University of Manitoba
730 William Avenue
Winnipeg, Manitoba
R3E 0W3

Dear Sir:

The subject of the use of animals in medical research and product testing has become increasingly topical recently. This has resulted in groups taking the extreme positions, either insisting on no animal use or the absolute value of animals. Such polarization contributes little or nothing to concrete scientific advances.

The Joseph F. Morgan Research Foundation was formed to take the middle ground which recognizes both the use of animals as necessary for the foreseeable future and that the efficient use of up-to-date non-animal research and testing techniques is of increasing importance. Such techniques will both reduce the numbers of animals used and the stress on those which are required. Along with this would go increases in cost efficiency and the potential for enhanced levels of public safety.

We are at present putting together an initial newsletter (programs) for the information of those responsible for product safety testing, regulatory matters and environmental quality, on the rapidly evolving newer testing methodologies and their validation, and we would like to effect an exchange of information and newsletters with you. I enclose a report written by Dr. John Gilman our Executive Director for the Health Protection Branch of Health and Welfare Canada and suggest that this may be of interest for you to review. Further copies may be obtained at:

Publications Division
Health and Welfare Canada
19th Floor, Jeanne Mance Building
Tunney's Pasture
Ottawa, Ontario K1A 0K9

ANNOUNCEMENT

CALL FOR APPLICATIONS FOR CSI TRAVEL ASSISTANCE TO THE

VIIIth INTERNATIONAL CONGRESS OF IMMUNOLOGY

(Budapest, August 23-30, 1992)

At its last meeting, the CSI Council approved funds for travel assistance to the VIIIth Congress for CSI members falling into the following categories:

- (a) Young staff members, within 5 years of their first academic appointment.
- (b) Post-doctoral fellows
- (c) Graduate students

Applications should consist of:

For staff members: A letter of intent and a curriculum vitae including a list of publications and an abstract* of the research to be presented at the Congress.

For post-doctoral fellows and graduate students: A letter of intent, a curriculum vitae including a list of publications, a letter of recommendation from the supervisor and an abstract* of the research to be presented at the Congress.

All documentation should be in quadruplicate and should be sent by:

November 1, 1991

to

Dr. R.G. Miller
Ontario Cancer Institute
500 Sherbourne Street
Toronto, Ontario
M4X 1K9

* Abstracts should be copies of the original prepared for the VIIIth Congress. Should official abstract forms not be available by November 1, 1991, an abstract on plain paper, single spaced of 14x12 cm should be provided.

ANNOUNCEMENT

Bursaries for VIIIth International Congress of Immunology (Budapest August 23-30, 1992)

The International Union of Immunological Societies (IUIS) will administer a program of limited financial assistance* to those who would otherwise find it difficult to attend the VIIIth Congress. Those selected for an award will receive a complimentary registration and, in some cases, a cash award in addition (\$200-750 (US) depending upon the awardee's estimated travel costs). **Applications must be received by November 30, 1991.** Decision letters will be mailed by December 15, 1991, but funds will be distributed only at the Congress site.

* The assistance program is supported by the Hungarian Organizing Committee (100 registrations), the IUIS (\$15,000) and the Europ. Fed. Immunol. Soc. (\$10,000)

To apply:

1. Complete the form (below) legibly and in English.
2. Enclose two (2) self-addressed adhesive mailing labels
3. Send all material to:

IUIS Bursaries, c/o AAI
9650 Rockville Pike
Bethesda, MD
USA 20814

APPLICATION FORM

Name: _____ Doctoral Degree(Yr): _____
(family, given)

Current Affiliation: _____
(Department, Institution)

Academic Rank: _____ Teaching responsibilities? No Yes
(Student? Faculty?) (Circle one)

Published research: No Yes (If "yes", list five (5) most recently published papers
(Circle one) on a separate sheet)

Invited Participant? _____
Sympos. Spk? Wkshop Chr? If neither, write "NO"

Name of Department Head

Signature of Department Head

Signature of applicant

(Photocopies of this form may be used)

LATE OR INCOMPLETE APPLICATIONS CANNOT BE CONSIDERED

CANADIAN SOCIETY FOR IMMUNOLOGY

APPLICATION FOR MEMBERSHIP



SOCIETE CANADIENNE D'IMMUNOLOGIE

DEMANDE D'ADHESION

Name of Applicant/Nom du Candidat _____

Position/Poste _____

Institution _____

Mailing Address and Telephone Number/Adresse Postale et Numero de Telephone _____

Signature of Applicant (Date) _____

Signature du Candidat (Date) _____

Sponsors (2 Members of The Canadian Society for Immunology)
Parrains (2 Membres de la Societe Canadienne d'Immunologie)

1. Name/Nom _____	2. Name/Nom _____
Address/Adresse _____	Address/Adresse _____
Signature _____	Signature _____

Category/Categorie

1. Member/Membre _____	2. Associate Member/Membre Associe _____
3. Emeritus Member/Membre Emerite _____	4. Student Member/Membre Etudiant _____

Applicants should append a curriculum vitae and a list of publications with full titles. 11 complete applications with appendices should be submitted. Student applicants need only submit one complete application with appendices. Applications will be considered in November and March.

Les candidats doivent joindre un curriculum vitae et une liste des publications incluant les titres. Veuillez completer ce formulaire, obtenir les signatures des parrains, et le faire parvenir en 11 copies (y compris les appendices). Les etudiants doivent soumettre une seule copie du demande complete avec l'information additionnelle requise. Les demandes d'adhesion seront examinees, en Novembre et Mars.

To/A: CSI c/o Dr. J. A. Wilkins
RDU Research Laboratory
RR 014, 800 Sherbrook Street
Winnipeg, MB
R3A 1M4